Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus STOBOCLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus STOBOCLO.
CAPEX vs STOBOCLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
STOBOCLO (bupivacaine and meloxicam) is a dual-acting local anesthetic and NSAID combination. Bupivacaine blocks sodium channels in nerve fibers, preventing nerve impulse conduction and producing local anesthesia. Meloxicam inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing anti-inflammatory and analgesic effects.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Adults: 5 mg orally once daily, with or without food. Maximum dose: 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life is 12-18 hours in adults with normal renal function, requiring dose adjustment in renal impairment.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal excretion of unchanged drug accounts for 60-70% of elimination; fecal/biliary excretion accounts for 20-30%; the remainder is metabolized hepatically.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid